Zekun Jiang1, Bao Wang2, Xiao Han3, Peng Zhao4, Meng Gao4, Yi Zhang5, Ping Wei5, Chuanjin Lan4, Yingchao Liu6, Dengwang Li7. 1. Shandong Key Laboratory of Medical Physics and Image Processing, Shandong Institute of Industrial Technology for Health Sciences and Precision Medicine, School of Physics and Electronics, Shandong Normal University, East Wenhua Road 88, Jinan, 250014, Shandong, China. 2. Department of Radiology, Qilu Hospital of Shandong University, Jinan, Shandong, China. 3. Department of Experiment, Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi, China. 4. Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jingwu Road 324, Jinan, 250021, Shandong, China. 5. Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. 6. Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jingwu Road 324, Jinan, 250021, Shandong, China. yingchaoliu@email.sdu.edu.cn. 7. Shandong Key Laboratory of Medical Physics and Image Processing, Shandong Institute of Industrial Technology for Health Sciences and Precision Medicine, School of Physics and Electronics, Shandong Normal University, East Wenhua Road 88, Jinan, 250014, Shandong, China. dengwang@sdnu.edu.cn.
Abstract
OBJECTIVES: To develop and validate a multimodality MRI-based radiomics approach to predicting the posttreatment response of lung cancer brain metastases (LCBM) to gamma knife radiosurgery (GKRS). METHODS: We retrospectively analyzed 213 lesions from 137 patients with LCBM who received GKRS between January 2017 and November 2020. The data were divided into a primary cohort (102 patients with 173 lesions) and an independent validation cohort (35 patients with 40 lesions) according to the time of treatment. Benefit result was defined using pretreatment and 3-month follow-up MRI images based on the Response Assessment in Neuro-Oncology Brain Metastases criteria. Valuable radiomics features were extracted from pretreatment multimodality MRI images using random forests. Prediction performance among the radiomics features of tumor core (RFTC) and radiomics features of peritumoral edema (RFPE) together was evaluated separately. Then, the random forest radiomics score and nomogram were developed through the primary cohort and evaluated through an independent validation cohort. Prediction performance was evaluated by ROC curve, calibration curve, and decision curve. RESULTS: Gender (p = 0.018), histological subtype (p = 0.009), epidermal growth factor receptor mutation (p = 0.034), and targeted drug treatment (p = 0.021) were significantly associated with posttreatment response. Adding RFPE to RFTC showed improved prediction performance than RFTC alone in primary cohort (AUC = 0.848 versus AUC = 0.750; p < 0.001). Finally, the radiomics nomogram had an AUC of 0.930, a C-index of 0.930 (specificity of 83.1%, sensitivity of 87.3%) in primary cohort, and an AUC of 0.852, a C-index of 0.848 (specificity of 84.2%, sensitivity of 76.2%) in validation cohort. CONCLUSIONS: Multimodality MRI-based radiomics models can predict the posttreatment response of LCBM to GKRS. KEY POINTS: • Among the selected radiomics features, texture features basically contributed the dominant force in prediction tasks (80%), especially gray-level co-occurrence matrix features (40%). • Adding RFPE to RFTC showed improved prediction performance than RFTC alone in primary cohort (AUC = 0.848 versus AUC = 0.750; p < 0.001). • The multimodality MRI-based radiomics nomogram showed high accuracy for distinguishing the posttreatment response of LCBM to GKRS (AUC = 0.930, in primary cohort; AUC = 0.852, in validation cohort).
OBJECTIVES: To develop and validate a multimodality MRI-based radiomics approach to predicting the posttreatment response of lung cancer brain metastases (LCBM) to gamma knife radiosurgery (GKRS). METHODS: We retrospectively analyzed 213 lesions from 137 patients with LCBM who received GKRS between January 2017 and November 2020. The data were divided into a primary cohort (102 patients with 173 lesions) and an independent validation cohort (35 patients with 40 lesions) according to the time of treatment. Benefit result was defined using pretreatment and 3-month follow-up MRI images based on the Response Assessment in Neuro-Oncology Brain Metastases criteria. Valuable radiomics features were extracted from pretreatment multimodality MRI images using random forests. Prediction performance among the radiomics features of tumor core (RFTC) and radiomics features of peritumoral edema (RFPE) together was evaluated separately. Then, the random forest radiomics score and nomogram were developed through the primary cohort and evaluated through an independent validation cohort. Prediction performance was evaluated by ROC curve, calibration curve, and decision curve. RESULTS: Gender (p = 0.018), histological subtype (p = 0.009), epidermal growth factor receptor mutation (p = 0.034), and targeted drug treatment (p = 0.021) were significantly associated with posttreatment response. Adding RFPE to RFTC showed improved prediction performance than RFTC alone in primary cohort (AUC = 0.848 versus AUC = 0.750; p < 0.001). Finally, the radiomics nomogram had an AUC of 0.930, a C-index of 0.930 (specificity of 83.1%, sensitivity of 87.3%) in primary cohort, and an AUC of 0.852, a C-index of 0.848 (specificity of 84.2%, sensitivity of 76.2%) in validation cohort. CONCLUSIONS: Multimodality MRI-based radiomics models can predict the posttreatment response of LCBM to GKRS. KEY POINTS: • Among the selected radiomics features, texture features basically contributed the dominant force in prediction tasks (80%), especially gray-level co-occurrence matrix features (40%). • Adding RFPE to RFTC showed improved prediction performance than RFTC alone in primary cohort (AUC = 0.848 versus AUC = 0.750; p < 0.001). • The multimodality MRI-based radiomics nomogram showed high accuracy for distinguishing the posttreatment response of LCBM to GKRS (AUC = 0.930, in primary cohort; AUC = 0.852, in validation cohort).
Authors: Philippe Lambin; Ralph T H Leijenaar; Timo M Deist; Jurgen Peerlings; Evelyn E C de Jong; Janita van Timmeren; Sebastian Sanduleanu; Ruben T H M Larue; Aniek J G Even; Arthur Jochems; Yvonka van Wijk; Henry Woodruff; Johan van Soest; Tim Lustberg; Erik Roelofs; Wouter van Elmpt; Andre Dekker; Felix M Mottaghy; Joachim E Wildberger; Sean Walsh Journal: Nat Rev Clin Oncol Date: 2017-10-04 Impact factor: 66.675
Authors: Roelof J Beukinga; Jan Binne Hulshoff; Véronique E M Mul; Walter Noordzij; Gursah Kats-Ugurlu; Riemer H J A Slart; John T M Plukker Journal: Radiology Date: 2018-03-14 Impact factor: 11.105
Authors: Jaap D Zindler; Arthur Jochems; Frank J Lagerwaard; Rosemarijne Beumer; Esther G C Troost; Daniëlle B P Eekers; Inge Compter; Peter-Paul van der Toorn; Marion Essers; Bing Oei; Coen W Hurkmans; Anna M E Bruynzeel; Geert Bosmans; Ans Swinnen; Ralph T H Leijenaar; Philippe Lambin Journal: Radiother Oncol Date: 2017-02-23 Impact factor: 6.280
Authors: Ke Nie; Liming Shi; Qin Chen; Xi Hu; Salma K Jabbour; Ning Yue; Tianye Niu; Xiaonan Sun Journal: Clin Cancer Res Date: 2016-05-16 Impact factor: 12.531
Authors: Wenya Linda Bi; Ahmed Hosny; Matthew B Schabath; Maryellen L Giger; Nicolai J Birkbak; Alireza Mehrtash; Tavis Allison; Omar Arnaout; Christopher Abbosh; Ian F Dunn; Raymond H Mak; Rulla M Tamimi; Clare M Tempany; Charles Swanton; Udo Hoffmann; Lawrence H Schwartz; Robert J Gillies; Raymond Y Huang; Hugo J W L Aerts Journal: CA Cancer J Clin Date: 2019-02-05 Impact factor: 508.702